These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21108578)

  • 1. Etoricoxib-induced fixed drug eruption with positive lesional patch tests.
    Calistru AM; Cunha AP; Nogueira A; Azevedo F
    Cutan Ocul Toxicol; 2011 Jun; 30(2):154-6. PubMed ID: 21108578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed drug eruption by etoricoxib confirmed by patch test.
    Sousa AS; Cardoso JC; Gouveia MP; Gameiro AR; Teixeira VB; Gonçalo M
    An Bras Dermatol; 2016; 91(5):652-654. PubMed ID: 27828643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing.
    Andrade P; Gonçalo M
    Contact Dermatitis; 2011 Feb; 64(2):118-20. PubMed ID: 21210830
    [No Abstract]   [Full Text] [Related]  

  • 4. Etoricoxib-induced fixed drug eruption: Report of seven cases.
    Martínez Antón MD; Galán Gimeno C; Sánchez de Vicente J; Jáuregui Presa I; Gamboa Setién PM
    Contact Dermatitis; 2021 Mar; 84(3):192-195. PubMed ID: 32666601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed drug eruption secondary to etoricoxib.
    Rawlings N; Joshi S; Sandison A; Carey B
    Br J Oral Maxillofac Surg; 2024 Jul; 62(6):571-574. PubMed ID: 38816329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoricoxib-induced erythema-multiforme-like eruption.
    Thirion L; Nikkels AF; Piérard GE
    Dermatology; 2008; 216(3):227-8. PubMed ID: 18182814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoricoxib-induced acute generalized exanthematous pustulosis.
    Mäkelä L; Lammintausta K
    Acta Derm Venereol; 2008; 88(2):200-1. PubMed ID: 18311467
    [No Abstract]   [Full Text] [Related]  

  • 8. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
    Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 10. Fixed drug eruption and generalised erythema following etoricoxib.
    Augustine M; Sharma P; Stephen J; Jayaseelan E
    Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
    [No Abstract]   [Full Text] [Related]  

  • 11. Probable etoricoxib-induced fixed drug eruption involving the oral mucosa: A case report.
    Perks A; Bates TJ; Velangi S; Brown RM; Poveda-Gallego A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Apr; 131(4):e100-e107. PubMed ID: 33468439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
    Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
    Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed drug eruption to cetirizine with positive lesional patch tests to the three piperazine derivatives.
    Cravo M; Gonçalo M; Figueiredo A
    Int J Dermatol; 2007 Jul; 46(7):760-2. PubMed ID: 17614812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
    Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
    Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal exfoliation as a selective reaction to etoricoxib.
    Patanè M; Isola S; Gangemi S; Minciullo PL
    J Clin Pharm Ther; 2016 Dec; 41(6):722-724. PubMed ID: 27576781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs.
    Corzo JL; Zambonino MA; Muñoz C; Mayorga C; Requena G; Urda A; Gallego C; Blanca M; Torres MJ
    Br J Dermatol; 2014 Mar; 170(3):725-9. PubMed ID: 24116718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
    Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
    J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.